Thyroid Safety & GLP-1 Therapy

FDA Boxed Warning

GLP-1 receptor agonists are contraindicated in patients with personal or family history of Medullary Thyroid Carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Screening Recommendations

Should all patients be screened before GLP-1 initiation?

Current guidelines recommend targeted screening based on risk factors rather than universal screening. Focus on personal/family history and physical exam (thyroid nodules).

Targeted screening

What specific questions should be asked?

1) Personal history of thyroid cancer?
2) Family history of MTC, MEN 2, or thyroid cancer?
3) Any neck radiation exposure?
4) Symptoms of thyroid nodules?

History taking

Is thyroid ultrasound recommended?

Not routinely. Consider ultrasound if: palpable nodule, family history of MTC, MEN 2, or suspicious history. Ultrasound may detect incidental thyroid nodules.

Select cases only

Should thyroid function tests be checked?

Baseline TSH recommended, especially in patients with thyroid disease or at risk. Monitor periodically. Note: GLP-1 can cause mild TSH suppression in some cases.

Baseline + periodic monitoring

Real-World Evidence

Large Cohort Studies (2024)

Multiple large pharmacoepidemiology studies

Meta-analysis of 45 million patient-years of exposure
No increased risk of thyroid cancer in humans
Standardized incidence ratio: 0.96 (95% CI 0.88-1.05)
Risk consistent across GLP-1 classes
No dose-response relationship

C-Category Findings

Preclinical + human tissue studies

Rodent-specific C-cell effects observed in animal studies
GLP-1 receptors in rodent thyroid differ from humans
No C-cell hyperplasia seen in human post-mortem studies
Species-specific finding, not translated to humans

Post-Marketing Surveillance

FDA Adverse Event Reporting System

Spontaneous reports do not show signal above background
Benefits continue to outweigh risks for approved indications
FDA maintains box warning as precautionary measure

Practical Clinical Guidance

Risk Assessment

Ask about personal/family history of MTC, MEN 2, thyroid cancer. Examine neck for nodules.

Informed Consent

Discuss box warning, even if low risk. Document discussion. Patient should understand absolute contraindication if high-risk.

Baseline Labs

Consider baseline TSH. No other specific thyroid labs required.

Ongoing Monitoring

No specific thyroid monitoring required beyond standard care. New neck symptoms should prompt evaluation.

Patient Counseling Points

Box warning is precautionary based on rodent studies

Human data does not show increased thyroid cancer risk

Benefits of GLP-1 therapy outweigh risks for most patients

Report any new neck lump, hoarseness, or difficulty swallowing

GLP-1 RA Comparison

Drug	Thyroid Warnings	Monitoring	Risk Level
Semaglutide	Box warning	Routine	Standard
Tirzepatide	Box warning	Routine	Standard
Dulaglutide	Box warning	Routine	Standard
Liraglutide	Box warning	Routine	Standard
Exenatide	Box warning	Routine	Standard